CD BioGlyco has rolled out a newly designed nucleic acid drug delivery system for siRNA- and mRNA-based therapeutics.
Built around refined glycosylation chemistry, the platform focuses on improving how molecules like siRNA and mRNA are brought into target cells. Rather than tweaking existing methods, the company has opted for a ground-up redesign that reflects recent lab needs—especially in gene-targeted treatments and RNA-based vaccines.
In many labs, researchers working with nucleic acid drugs run into the same set of problems: the molecules break down too easily, don’t always reach the intended cells, or work inconsistently across tissues. These issues limit how far projects can go. CD BioGlyco’s new system addresses these gaps using GalNAc sugar ligands for liver targeting and a modular assembly method known as GlycoCLICK™, which allows for tighter control over how the drugs are built and released.
The new platform is built around GalNAc-L96, CD BioGlyco’s proprietary triantennary ligand used to improve liver-targeted siRNA delivery. This structure is specifically designed to bind the ASGPR receptor on hepatocytes, facilitating efficient and selective uptake. Paired with the GlycoCLICK™ platform, GalNAc-L96 enables modular assembly of oligonucleotide therapies, giving researchers greater flexibility when fine-tuning drug performance and minimizing off-target exposure.
While the platform was built with liver-targeted treatments in mind, its modular design means it can be adapted for other uses too. Teams working in cancer biology, infectious disease, and metabolic disorders can use the same core chemistry to deliver payloads into different types of cells. In preclinical collaborations, the system has already shown better uptake and more even response across sample groups—especially in studies involving mRNA vaccines and gene silencing tools.
“This wasn’t about adding a feature or two,” said Anna, a spokesperson for CD Bioglyco. “We kept seeing the same problems show up in nucleic acid drug delivery—especially when researchers moved from cell culture to animal models. So we stepped back and rebuilt the process. What we’ve got now is something that actually fits the pace and complexity of current RNA-based research.”
The company is currently working with several academic and biotech groups to refine its system across more cell types and disease areas. For labs looking to test nucleic acid therapies with tighter control and cleaner readouts, CD BioGlyco’s new platform is now available for collaboration and pilot projects.
More information about the system and its development pipeline can be found at:
https://www.bioglyco.com/nucleic-acid-drug-delivery-products.html
Comments
0 comment